Comparison of amikacin dosing regimens in neutropenic guinea pigs with Escherichia coli infection

American Journal of Veterinary Research

Volumn 59, Issue 6, 1998, Pages 750-755

  McClure, J T ^a   Rosin, Eberhard ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CALCULATION; COLONY FORMING UNIT; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; ESCHERICHIA COLI; FEMALE; GUINEA PIG; INOCULATION; MALE; NEUTROPENIA; NONHUMAN; TREATMENT PLANNING;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESCHERICHIA COLI INFECTIONS; FEMALE; GUINEA PIGS; HALF-LIFE; LEUKOCYTE COUNT; MALE; METABOLIC CLEARANCE RATE; NEUTROPENIA; NEUTROPHILS; REFERENCE VALUES;

ANIMALIA; BACTERIA (MICROORGANISMS); CAVIA; CAVIA PORCELLUS; ESCHERICHIA COLI; SUS SCROFA;

EID: 0031813747     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Frame PT, Phair JP, Watanakunakorn C, et al. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 1977;135:952-956.
2. Reiner NE, Bloxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978;4(Suppl A):85-101.
3. Wood CA, Norton DR, Kohlhepp SJ, et al. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988;158:13-22.
4. Bennett WM, Plamp CE, Gilbert DN, et al. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979; 140:576-580.
5. Marik PE, Lipman J, Kobilski S, et al. A prospective randomized study comparing once-versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991;28:753-764.
6. Prins JM, Bueller HR, Kuijper EJ, et al. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections a randomized clinical trial. J Antimicrob Chemother 1994;33:823-835.
7. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45:22-27.
8. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991;27(Suppl C):41-47.
9. ter Braak EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990;89:58-66.
10. De Broe ME, Giuliano RA, Verpooten GA. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986;80:115-118.
11. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-840.
12. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989;24: 281-293.
13. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399-405.
14. Hustinx WNM, Hoepelman IM. Aminoglycoside dosage regimens: is once a day enough? Clin Pharmacokinet 1993;25:427-432.
15. Potel G, Caillon J, Fantin B, et al. Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation. Antimicrob Agents Chemother 1991;35:111-116.
16. Garraffo R, Drugeon HB, Dellamonica P, et al. Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother 1990;34:614-621.
17. Rosin E, Ebert S, Uphoff TS, et al. Penetration of antibiotics into the surgical wound in a canine model. Antimicrob Agents Chemother 1989;33:700-704.
18. Jackson GG, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990;162:408-413.
19. Gerber AU. Impact of the antibiotic dosage schedule on efficacy in experimental soft tissue infections. Scand J Infect Dis Suppl 1991;74:147-154.
20. Hancock RE. Aminoglycoside uptake and mode of action with special reference to streptomycin and gentamicin. I. Antagonists and mutants. J Antimicrob Chemother 1981;8:249-276.
21. Bryan LE, Kwan S. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother 1983;23:835-845.
22. Daikos GL, Jackson GG, Lolans VT, et al. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990;162:414-420.
23. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991;35:117-123.
24. Karlowsky JA, Zhanel GG, Davidson RJ, et al. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994;38:1165-1168.
25. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985;15(Suppl A):37-46.
26. Vogelman B, Gudmundsson S, Turnidge J, et al. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988;157:287-298.
27. Karlowsky JA, Zhanel GG, Davidson RJ, et al. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother 1994;33: 937-947.
28. Barmada S, Kohlhepp S, Leggett J, et al. Correlation of tobramycin-induced inhibition of protein synthesis with postantibiotic effect in Escherichia coli. Antimicrob Agents Chemother 1993;37: 2678-2683.
29. Isaksson B, Hanberger H, Mailer R, et al. Synergic postantibiotic effect of amikacin in combination with beta-lactam antibiotics on gram-negative bacteria. J Antimicrob Chemother 1991;28: 25-34.
30. Fantin B, Ebert S, Leggett J, et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 1991;27:829-836.
31. Hanberger H. Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time. Scand J Infect Dis Suppl 1992;81:1-52.
32. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991;27(Suppl C):29-40.
33. Kapusnik JE, Hackbarth CJ, Chambers HF, et al. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 1988;158:7-12.
34. Blaser J, Stone BB, Zinner SH. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother 1985;27:343-349.
35. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-99.
36. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-1060.
37. Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-847.
38. Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918-932.
39. Gerber AU, Craig WA, Brugger HP, et al. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 1983;147: 910-917.
40. Herscovia L, Grise G, Thauvin C. Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis. Scand J Infect Dis 1988;20:205-212.
41. Roosendaal R, Bakker-Woudenberg I, Berghe-van Raffe M. Impact of the dosage schedule on the efficiacy of ceftazidime, gentamicin, and ciprofloxacin on Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989; 8:878-887.
42. Campbell B, Bartholow S, Rosin E. Bacterial killing of once daily gentamicin dosage in guinea pigs with Escherichia coli infection. Am J Vet Res 1996;57:1627-1630.
43. Maller R, Ahrne H, Eilard T, et al. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. Scandinavian Amikacin Once Daily Study Group. J Antimicrob Chemother 1991;27(Suppl C):121-128.
44. Giamarellou H, Yiallouros K, Petrikkos G, et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother 1991;27(Suppl C):73-79.
45. Nordstrom L, Ringberg H, Cronberg S, et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25:159-173.
46. Aiba T, Itoga Y, Shimizu H, et al. Renal handling of tobramycin in the isolated perfused rat kidney. J Pharm Sci 1994;83:723-726.
47. Giuliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986;236:470-475.
48. Strum AW. Netilmicin in the treatment of gram-negative bacteremia: single daily verus multiple daily dosage. J Infect Dis 1989;159:931-937.
49. Hollender LF, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother 1989;23:773-783.
50. Tulkens PM. Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data. Scand J Infect Dis Suppl 1990; 74:249-257.
51. Dionisotti S, Bamonte F, Leung P, et al. Aminoglycoside dosing regimen and pharmacokinetic parameters in the guinea pig. Chemotherapy 1990;36:33-40.
52. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc 1991;66:1158-1164.
53. Paradelis AG, Triantaphyllidis CJ, Mironidou M, et al. Interaction of aminoglycoside antibiotics and calcium channel blockers at the neuromuscular junctions. Methods Find Exp Clin Pharmacol 1988;10:687-690.
54. Brown MP, Embertson RM, Gronwall RR, et al. Amikacin sulfate in mares: pharmacokinetics and body fluid and endometrial concentrations after repeated intramuscular administration. Am J Vet Res 1984;45:1610-1613.
55. Orsini JA, Soma LR, Rourke JE, et al. Pharmacokinetics of amikacin in the horse following intravenous and intramuscular administration. J Vet Pharmacol Ther 1985;8:194-201.
56. Davis RL, Lehmann D, Stidley CA, et al. Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Antimicrob Agents Chemother 1991;35:944-947.
57. Marik PE, Havlik I, Monteagudo FSE, et al. The pharmacokinetics of amikacin in critically ill adult and pediatric patients: comparison of once-versus twice-daily dosing regimens. J Antimicrob Chemother 1991;35:944-947.
58. Wichtel MG, Breuhaus BA, Aucoin DP. Relation between pharmacokinetics of amikacin sulfate and sepsis score in clinically normal and hospitalized neonatal foals. J Am Vet Med Assoc 1992; 200:1339-1343.
59. Green SL, Conlon PD. Clinical pharmacokinetics of amikacin in hypoxic premature foals. Equine Vet J 1993;25:276-280.
60. Bressolle F, Gouby A, Martinez JM, et al. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother 1996;40:1682-1689.